|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.383 GBX | -2.60% |
|
-2.60% | +9.57% |
| 11/05 | Central Asia Metals cancels share premium account | AN |
| 11/05 | Poolbeg Pharma Receives Patent Grant For POLB 001 Cancer Immunotherapy-Induced CRS In Canada | CI |
Projected Income Statement: Poolbeg Pharma PLC
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| EBITDA 1 | - | -4.96 | -4.66 | -5.997 | -5.417 | -5.6 |
| Change | - | - | 6.05% | -28.69% | 9.67% | -3.38% |
| EBIT 1 | - | -4.986 | -4.686 | -6.111 | -5.476 | -5.9 |
| Change | - | - | 6.02% | -30.41% | 10.39% | -7.74% |
| Interest Paid | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.777 | -4.505 | -5.944 | -5.774 | -5.75 |
| Change | - | - | 5.69% | -31.94% | 2.86% | 0.42% |
| Net income 1 | -2.336 | -4.686 | -3.931 | -5.79 | -5.695 | -5.75 |
| Change | - | -100.6% | 16.11% | -47.29% | 1.64% | -0.97% |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | 20/05/25 | 28/04/26 | - |
1GBP in Million
Estimates
Forecast Balance Sheet: Poolbeg Pharma PLC
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | -16.2 | -12.2 | -7.82 | -7.71 | -1.95 |
| Change | - | - | 24.69% | 35.9% | 1.41% | 72.73% |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | 20/05/25 | 28/04/26 | - |
1GBP in Million
Estimates
Cash Flow Forecast: Poolbeg Pharma PLC
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| CAPEX 1 | 0.597 | 0.175 | 0.129 | 0.08 | 0.1 |
| Change | - | -70.69% | -26.29% | -37.98% | 0% |
| Free Cash Flow (FCF) 1 | -4.965 | -4.556 | -4.775 | -4.841 | -5.9 |
| Change | - | 8.24% | -4.81% | -1.38% | -15.69% |
| Announcement Date | 30/03/23 | 30/04/24 | 20/05/25 | 28/04/26 | - |
1GBP in Million
Estimates
Forecast Financial Ratios: Poolbeg Pharma PLC
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
Profitability | ||||||
| EBITDA Margin (%) | - | - | - | - | - | - |
| EBIT Margin (%) | - | - | - | - | - | - |
| EBT Margin (%) | - | - | - | - | - | - |
| Net margin (%) | - | - | - | - | - | - |
| FCF margin (%) | - | - | - | - | - | - |
| FCF / Net Income (%) | - | 105.95% | 115.9% | 82.47% | 85% | 102.61% |
Profitability | ||||||
| ROA | - | - | - | - | - | - |
| ROE | - | -22.91% | -24% | -48.83% | -63.72% | -180.6% |
Financial Health | ||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - |
Capital Intensity | ||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | -12.04% | -3.76% | -2.15% | -1.48% | -1.79% |
| CAPEX / FCF (%) | - | -12.02% | -3.84% | -2.7% | -1.65% | -1.69% |
Items per share | ||||||
| Cash flow per share 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Book Value Per Share 1 | - | 0.0366 | 0.03 | 0.0186 | 0.0143 | 0.004 |
| Change | - | - | -18.03% | -38.17% | -22.91% | -66.67% |
| EPS 1 | -0.0074 | -0.0094 | -0.0079 | -0.0116 | -0.0094 | -0.0083 |
| Change | - | -27.03% | 15.96% | -46.84% | 18.97% | 16.16% |
| Nbr of stocks (in thousands) | 5,00,000 | 5,00,000 | 5,00,000 | 5,00,000 | 7,05,104 | 7,05,104 |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | 20/05/25 | 28/04/26 | - |
1GBP
Estimates
| 2025 * | 2026 * | |
|---|---|---|
| P/E ratio | -4.26x | -5.42x |
| PBR | 2.8x | 11.3x |
| EV / Sales | - | - |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0450GBP
Average target price
0.1900GBP
Spread / Average Target
+322.22%
Annual profits - Rate of surprise
- Stock Market
- Equities
- POLB Stock
- Financials Poolbeg Pharma PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition